| Prev Close | 2.29 |
| Open | 2.35 |
| Day Low/High | 2.17 / 2.35 |
| 52 Wk Low/High | 1.90 / 8.50 |
| Volume | 46.72K |
| Avg Volume | 196.70K |
| Exchange | OTC |
| Shares Outstanding | 5.72M |
| Market Cap | 13.28M |
| EPS | -6.50 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Soligenix Initiates Pivotal Phase 3 Clinical Trial Of SGX942 (Dusquetide) For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
"DOM-INNATE" study opens patient enrollment
Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine
Awarded $2M to Advance Preclinical Efficacy Studies
Soligenix Announces Publication Of Its Phase 2 Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
At 12 Months SGX942 Found to be Safe and Well Tolerated with Multiple Potential Ancillary Benefits
Soligenix Receives Japanese Patent For ThermoVax® Vaccine Heat Stabilization Platform Technology
Patent describes application of ThermoVax® with RiVax®
Soligenix Receives FDA Protocol Clearance Of Pivotal Phase 3 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
Trial Targeted to Begin in Second Quarter of 2017
Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results
Highlighted by Revenues of $10.4 Million
CEO Sells $6.1M Worth of Liberty Media
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
